{"company": {"org_id": "T004812046", "org_name_cn": "益方生物科技(上海)股份有限公司", "org_short_name_cn": "益方生物", "org_name_en": "Inventisbio Co.,Ltd.", "org_short_name_en": "InventisBio", "main_operation_business": "创新药物的研发、生产和销售。", "operating_scope": "　　许可项目：药品生产；药品批发；药品零售；药品进出口。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准）一般项目：生物技术（人体干细胞、基因诊断与治疗技术开发和应用除外）、医药科技领域内的技术开发、技术服务、技术转让、技术交流、技术推广、技术服务。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）", "district_encode": "310115", "org_cn_introduction": "益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。", "legal_representative": "王耀林", "general_manager": "王耀林", "secretary": "江岳恒", "established_date": 1357833600000, "reg_asset": 578327844.0, "staff_num": 185, "telephone": "86-21-50778527", "postcode": "201203", "fax": "86-21-50778527", "email": "ir@inventisbio.com", "org_website": "www.inventisbio.com", "reg_address_cn": "上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室", "reg_address_en": null, "office_address_cn": "上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室", "office_address_en": null, "currency_encode": "019001", "currency": "CNY", "listed_date": 1658678400000, "provincial_name": "上海市", "actual_controller": "王耀林 (19.70%)，江岳恒 (4.64%)，代星 (3.54%)", "classi_name": "外资企业", "pre_name_cn": "益方生物科技(上海)有限公司", "chairman": "王耀林", "executives_nums": 10, "actual_issue_vol": 115000000.0, "issue_price": 18.12, "actual_rc_net_amt": 1982153370.0, "pe_after_issuing": null, "online_success_rate_of_issue": 0.04509015, "affiliate_industry": {"ind_code": "BK0040", "ind_name": "化学制药"}}}